Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTANASDAQ:NMRANASDAQ:RAPTNYSE:VNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$5.63+0.9%$6.10$4.09▼$17.24$120.11M0.69287,071 shs110,335 shsNMRANeumora Therapeutics$0.76+0.7%$1.09$0.62▼$17.19$123.35M2.891.48 million shs793,164 shsRAPTRAPT Therapeutics$0.92+4.8%$1.08$0.75▼$8.58$139.93M-0.291.28 million shs976,956 shsVNRXVolitionRx$0.46-4.9%$0.54$0.42▼$0.95$46.65M1.15173,253 shs129,884 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals+0.90%+7.65%-1.40%+9.96%-54.49%NMRANeumora Therapeutics+0.67%+15.55%-25.96%-62.06%-91.67%RAPTRAPT Therapeutics+4.84%+17.79%-24.50%-21.94%-88.63%VNRXVolitionRx-4.93%-3.14%-15.82%-24.96%-49.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTAEnanta Pharmaceuticals4.059 of 5 stars3.41.00.04.73.04.20.0NMRANeumora Therapeutics3.3484 of 5 stars4.11.00.00.02.93.31.3RAPTRAPT Therapeutics4.0633 of 5 stars3.13.00.04.22.51.71.3VNRXVolitionRx1.8975 of 5 stars3.40.00.00.02.22.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTAEnanta Pharmaceuticals 2.80Moderate Buy$17.25206.39% UpsideNMRANeumora Therapeutics 2.22Hold$9.291,117.64% UpsideRAPTRAPT Therapeutics 2.11Hold$4.00334.26% UpsideVNRXVolitionRx 2.75Moderate Buy$3.33619.94% UpsideCurrent Analyst Ratings BreakdownLatest VNRX, ENTA, RAPT, and NMRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025NMRANeumora TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/8/2025VNRXVolitionRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$2.50 ➝ $2.504/2/2025NMRANeumora TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$7.00 ➝ $1.003/31/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/20/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/12/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/10/2025NMRANeumora TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/10/2025RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/7/2025NMRANeumora TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral3/7/2025NMRANeumora TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.00 ➝ $2.003/4/2025NMRANeumora TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$4.00 ➝ $4.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTAEnanta Pharmaceuticals$66.59M1.80N/AN/A$5.24 per share1.07NMRANeumora TherapeuticsN/AN/AN/AN/A$3.07 per shareN/ARAPTRAPT Therapeutics$1.53M79.47N/AN/A$4.27 per share0.22VNRXVolitionRx$1.23M37.82N/AN/A($0.11) per share-4.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTAEnanta Pharmaceuticals-$116.04M-$4.95N/AN/AN/A-157.57%-75.53%-27.30%5/5/2025 (Estimated)NMRANeumora Therapeutics-$235.93M-$1.53N/AN/AN/AN/A-73.63%-68.97%5/6/2025 (Estimated)RAPTRAPT Therapeutics-$116.80M-$3.11N/AN/AN/AN/A-89.10%-76.13%5/8/2025 (Estimated)VNRXVolitionRx-$35.32M-$0.31N/A∞N/A-2,321.14%N/A-163.39%N/ALatest VNRX, ENTA, RAPT, and NMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025RAPTRAPT Therapeutics-$0.31N/AN/AN/AN/AN/A5/6/2025Q1 2025NMRANeumora Therapeutics-$0.40N/AN/AN/AN/AN/A5/5/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.16N/AN/AN/A$15.96 millionN/A3/6/2025Q4 2024NMRANeumora Therapeutics-$0.46-$0.37+$0.09-$0.37N/AN/A3/6/2025Q4 2024RAPTRAPT Therapeutics-$0.45-$1.14-$0.69-$1.14N/AN/A2/10/2025Q1 2025ENTAEnanta Pharmaceuticals-$1.16-$1.05+$0.11-$1.05$17.25 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/ARAPTRAPT TherapeuticsN/AN/AN/AN/AN/AVNRXVolitionRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTAEnanta PharmaceuticalsN/A5.475.47NMRANeumora TherapeuticsN/A10.9810.98RAPTRAPT TherapeuticsN/A9.909.90VNRXVolitionRxN/A0.220.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTAEnanta Pharmaceuticals94.99%NMRANeumora Therapeutics47.65%RAPTRAPT Therapeutics99.09%VNRXVolitionRx8.09%Insider OwnershipCompanyInsider OwnershipENTAEnanta Pharmaceuticals13.89%NMRANeumora Therapeutics26.40%RAPTRAPT Therapeutics6.60%VNRXVolitionRx12.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTAEnanta Pharmaceuticals16021.33 million18.37 millionOptionableNMRANeumora Therapeutics108161.75 million118.91 millionOptionableRAPTRAPT Therapeutics80132.01 million32.65 millionOptionableVNRXVolitionRx80100.75 million80.80 millionOptionableVNRX, ENTA, RAPT, and NMRA HeadlinesRecent News About These CompaniesVolitionRx enters new sales agreement, terminates old oneApril 24, 2025 | investing.comVolitionRx initiated with a Buy at H.C. WainwrightApril 8, 2025 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of VolitionRx (VNRX) with Buy RecommendationApril 8, 2025 | msn.comEarnings call transcript: VolitionRx revenue beats forecast in Q4 2024April 2, 2025 | investing.comVolitionRx (NYSE:VNRX) Receives "Buy" Rating from D. Boral CapitalApril 1, 2025 | marketbeat.comVolitionRx outlines 2025 licensing goals and targets cash neutrality with strategic expansionsApril 1, 2025 | msn.comVolitionRx Limited (VNRX) Q4 2024 Earnings Call TranscriptApril 1, 2025 | seekingalpha.comVolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business UpdateMarch 31, 2025 | prnewswire.com3VNRX : A Look Ahead: VolitionRX's Earnings ForecastMarch 28, 2025 | benzinga.comVolition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025March 28, 2025 | prnewswire.comInsider Buying: VolitionRx Limited (NYSE:VNRX) CEO Acquires 181,818 Shares of StockMarch 28, 2025 | insidertrades.comVolition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025March 27, 2025 | prnewswire.comVolitionRx Announces Pricing of up to $2.3 Million Registered Direct OfferingMarch 26, 2025 | prnewswire.comVolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business UpdateMarch 25, 2025 | prnewswire.comVolition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy IndustryMarch 21, 2025 | prnewswire.comVolition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung CancerMarch 20, 2025 | prnewswire.comVolition Proudly Sponsors the 44th ISICEM CongressMarch 17, 2025 | prnewswire.comVolition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet SystemsMarch 13, 2025 | prnewswire.comVolition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer TestMarch 11, 2025 | prnewswire.comVolition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First TimeMarch 4, 2025 | prnewswire.comVolition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual ConferenceFebruary 28, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBuffett’s Next Oil Bet: Why Occidental Is DifferentBy Jea Yu | April 8, 2025View Buffett’s Next Oil Bet: Why Occidental Is DifferentFundamentally Sound, These 5 Stocks Sold Off AnywayBy Thomas Hughes | April 23, 2025View Fundamentally Sound, These 5 Stocks Sold Off AnywayTop 3 S&P 500 Winners in a Losing MarketBy Ryan Hasson | April 9, 2025View Top 3 S&P 500 Winners in a Losing MarketOil Prices Are Tanking—These 3 Plays Could Fuel Your GainsBy Gabriel Osorio-Mazilli | April 9, 2025View Oil Prices Are Tanking—These 3 Plays Could Fuel Your Gains3 Stocks To Watch For When Tariffs Subside By Gabriel Osorio-Mazilli | April 25, 2025View 3 Stocks To Watch For When Tariffs Subside VNRX, ENTA, RAPT, and NMRA Company DescriptionsEnanta Pharmaceuticals NASDAQ:ENTA$5.63 +0.05 (+0.90%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$5.64 +0.00 (+0.09%) As of 04/28/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Neumora Therapeutics NASDAQ:NMRA$0.76 +0.01 (+0.67%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$0.76 -0.01 (-0.73%) As of 04/28/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.RAPT Therapeutics NASDAQ:RAPT$0.92 +0.04 (+4.84%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$0.95 +0.03 (+2.92%) As of 04/28/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb CompanyVolitionRx NYSE:VNRX$0.46 -0.02 (-4.93%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$0.47 +0.00 (+0.86%) As of 04/28/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Rebounds After Strong Earnings and Buyback Announcement Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? The Bear Market Has Only Just Started - Here's Why MarketBeat Week in Review – 04/21 - 04/25 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy Bears Can Reap Big Benefits With These 3 Short ETF Bets Why Institutions Are Buying Super Micro Computer Stock Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
